42.98

0.90% -0.39

After Hours: 42.98

Ionis Pharmaceuticals Inc (IONS)

Overview News Price History Option Chain Financials Discussions Forecast

Ionis Pharmaceuticals Inc stock is traded at $42.98, with a volume of 3.54M. It is down -0.90% in the last 24 hours and up +8.78% over the past month. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Previous Close:

$43.37

Open:

$44.37

24h Volume:

3.54M

Relative Volume:

2.02

Market Cap:

$6.84B

Revenue:

$705.14M

Net Income/Loss:

$-453.90M

P/E Ratio:

-14.14

EPS:

-3.04

Net Cash Flow:

$-551.29M

1W Performance:

+1.97%

1M Performance:

+8.78%

6M Performance:

+34.73%

1Y Performance:

-13.10%

1-Day Range:

$42.33

$44.98

1-Week Range:

$40.81

$45.66

52-Week Range:

$23.95

$51.62

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name

Ionis Pharmaceuticals Inc

Sector

Healthcare (1161)

Industry

Biotechnology (646)

Phone

(760) 931-9200

Address

2855 GAZELLE COURT, CARLSBAD, CA

Employee

927

Twitter

@ionispharma

Next Earnings Date

2024-11-06

Latest SEC Filings

IONS's Discussions on Twitter

Compare IONS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IONS Ionis Pharmaceuticals Inc	42.98	6.90B	705.14M	-453.90M	-551.29M	-3.04
VRTX Vertex Pharmaceuticals Inc	456.87	120.48B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	545.46	59.88B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	392.24	44.31B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	670.33	36.65B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	301.13	32.46B	3.81B	-644.79M	-669.77M	-6.24

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-01-25	Upgrade	Barclays	Equal Weight → Overweight
Apr-07-25	Initiated	H.C. Wainwright	Buy
Mar-31-25	Initiated	Redburn Atlantic	Neutral
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-16-24	Resumed	Jefferies	Buy
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral
Sep-29-23	Initiated	Raymond James	Strong Buy
Jul-31-23	Upgrade	Citigroup	Neutral → Buy
Jun-07-23	Resumed	Piper Sandler	Overweight
May-04-23	Upgrade	Citigroup	Sell → Neutral
Mar-21-23	Initiated	Bernstein	Underperform
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-09-22	Resumed	Morgan Stanley	Overweight
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-31-22	Resumed	Piper Sandler	Overweight
Mar-01-22	Initiated	Citigroup	Sell
Mar-01-22	Initiated	Guggenheim	Buy
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform
Dec-14-21	Upgrade	William Blair	Mkt Perform → Outperform
May-07-21	Upgrade	UBS	Sell → Neutral
Mar-01-21	Upgrade	Barclays	Underweight → Equal Weight
Dec-16-20	Initiated	UBS	Sell
Dec-15-20	Upgrade	Cowen	Market Perform → Outperform
Sep-14-20	Resumed	JP Morgan	Neutral
Sep-02-20	Initiated	The Benchmark Company	Hold
Jun-01-20	Resumed	Oppenheimer	Outperform
May-13-20	Initiated	RBC Capital Mkts	Outperform
Mar-05-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
Nov-07-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Sep-10-19	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-08-18	Reiterated	Stifel	Hold
Aug-07-18	Reiterated	Stifel	Hold
May-08-18	Downgrade	Evercore ISI	Outperform → In-line
Oct-06-17	Resumed	Goldman	Sell
Aug-17-17	Initiated	Evercore ISI	Outperform
Aug-09-17	Reiterated	Stifel	Hold
Mar-10-17	Downgrade	Goldman	Neutral → Sell
Dec-28-16	Reiterated	BMO Capital Markets	Outperform
Dec-27-16	Reiterated	Leerink Partners	Mkt Perform

View All

Ionis Pharmaceuticals Inc Stock (IONS) Latest News

Jul 31, 2025

Ionis Pharmaceuticals Reports Strong Earnings and Growth - TipRanks

Jul 31, 2025

Ionis raises 2025 revenue guidance to $850M with Tryngolza momentum and Donidalorsen launch on track - MSN

Jul 31, 2025

How does Ionis Pharmaceuticals Inc. compare to its industry peersAI Powered Tips With High Returns - jammulinksnews.com

Jul 31, 2025

Ionis (IONS) Q2 Revenue Soars 101% - The Globe and Mail

Jul 31, 2025

UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach - insights.citeline.com

Jul 31, 2025

Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook - TradingView

Jul 31, 2025

Ionis Pharmaceuticals stock price target raised to $65 from $50 at H.C. Wainwright - Investing.com Canada

Jul 31, 2025

Ionis reports second quarter 2025 financial results and highlights progress on key programs - BioSpace

Jul 31, 2025